Life Science Investor Suits Spiked In '17, Dechert Reports
The number of securities class actions investors filed against life sciences companies dramatically increased in 2017, reaching a record-high 88, according to a report recently released by Dechert LLP....To view the full article, register now.
Already a subscriber? Click here to view full article